These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37467793)

  • 1. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
    Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
    J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
    Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine pathway in depression: A systematic review and meta-analysis.
    Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
    Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
    Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
    Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
    Yun Y; Zhang Q; Zhao W; Ma T; Fan H; Bai L; Ma B; Qi S; Wang Z; An H; Yang F
    J Psychosom Res; 2022 Dec; 163():111069. PubMed ID: 36335711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
    Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
    Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders.
    Li Y; Wang L; Huang J; Zhang P; Zhou Y; Tong J; Chen W; Gou M; Tian B; Li W; Luo X; Tian L; Hong LE; Li CR; Tan Y
    Front Psychiatry; 2024; 15():1357293. PubMed ID: 38680780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
    Ryan KM; Allers KA; McLoughlin DM; Harkin A
    Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
    Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
    Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
    Sun Y; Drevets W; Turecki G; Li QS
    Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder.
    van den Ameele S; van Nuijs AL; Lai FY; Schuermans J; Verkerk R; van Diermen L; Coppens V; Fransen E; de Boer P; Timmers M; Sabbe B; Morrens M
    Bipolar Disord; 2020 Feb; 22(1):59-69. PubMed ID: 31398273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Metabolic Factor Kynurenic Acid of Kynurenine Pathway Predicts Major Depressive Disorder.
    Liu H; Ding L; Zhang H; Mellor D; Wu H; Zhao D; Wu C; Lin Z; Yuan J; Peng D
    Front Psychiatry; 2018; 9():552. PubMed ID: 30510519
    [No Abstract]   [Full Text] [Related]  

  • 16. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
    Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
    Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
    Öztürk M; Yalın Sapmaz Ş; Kandemir H; Taneli F; Aydemir Ö
    Int J Clin Pract; 2021 Apr; 75(4):e13739. PubMed ID: 32997876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
    Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
    PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress.
    Kucukkarapinar M; Yay-Pence A; Yildiz Y; Buyukkoruk M; Yaz-Aydin G; Deveci-Bulut TS; Gulbahar O; Senol E; Candansayar S
    J Neural Transm (Vienna); 2022 Aug; 129(8):1077-1089. PubMed ID: 35796878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid.
    Savitz J; Ford BN; Yeh HW; Akeman E; Cosgrove K; Clausen AN; Martell C; Kirlic N; Santiago J; Teague TK; Irwin MR; Paulus MP; Aupperle RL
    Psychol Med; 2022 Oct; 52(13):2500-2509. PubMed ID: 33234171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.